News
A UK watchdog is urging women on GLP-1 weight-loss drugs like Ozempic and Mounjaro to use effective forms of birth control after receiving more than 40 pregnancy-related reports linked to the ...
2d
MedPage Today on MSNSemaglutide Linked to Age-Related Macular Degeneration RiskOlder adults taking GLP-1 receptor agonists, primarily semaglutide (Rybelsus, Ozempic, Wegovy), had a small uptick in their ...
Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...
Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.
European Medicines Agency (EMA)'s safety committee (PRAC) has concluded its review of medicines containing semaglutide ...
By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...
23h
MedPage Today on MSNGLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA WarnsA potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...
A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...
The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...
Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...
Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...
A popular weight-loss drug may be changing how doctors treat obesity—but scientists are just starting to uncover exactly how ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results